Tirzepatide's GIP co-agonism appears to protect against diarrhea relative to semaglutide, even at higher weight loss
Your weight loss starts with a comprehensive medical evaluation
Heres what physicians should include in a consent discussion to reduce legal exposure: Without this level of transparency, providers risk being named in a lawsuit against Ozempic for lack of informed consent an increasingly common legal argument in these cases
Lowers oxidative stress, which is linked to autoimmune flare-ups
In the ATTAIN obesity trials, maintenance doses of 6 mg, 12 mg, and 36 mg were evaluated, with 36 mg producing the greatest weight loss
Nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, and indigestion are the most common, especially during dose changes, and usually ease over time